Abstract
Antiphospholipid syndrome is a systemic autoimmune disease with unclear etiology and complex pathogenesis. It can be a single nosological unit or in the context of another systemic disease of the connective tissue – most commonly systemic lupus erythematosus (SLE). The presence of antiphospholipid antibodies in pregnant women is associated with an increased rate of complications during pregnancy. The most common symptoms are preeclampsia and eclampsia, early spontaneous abortions and late fetal loss, in the absence or presence of a proven genetic defect for congenital thrombophilia and/or chromosomal diseases. A multidisciplinary approach and regular patient consultations are key factors in the follow-up and positive outcomes of pregnancy in women with SLE and antiphospholipid syndrome (APS). Timely treatment with corticosteroids, anticoagulants, antiаggregant agents, and intravenous immunoglobulins repeatedly increases the chance of successful completion of pregnancy with live birth.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
